Review Article. Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: What is the evidence?
Open Access
- 1 August 2004
- journal article
- review article
- Published by Wiley in Nephrology
- Vol. 9 (4), 190-197
- https://doi.org/10.1111/j.1440-1797.2004.00260.x
Abstract
Dialysis patients show a high prevalence of cardiovascular complications among which left ventricular hypertrophy is one of the most frequent and is independently predictive of mortality. A recent study indicates that partial regression of left ventricular hypertrophy improves mortality and reduces cardiovascular events in end-stage renal disease (ESRD) patients, suggesting the importance of targeting therapeutic strategies to reduce cardiac hypertrophy and improve the outcome in these patients. The pathogenesis of left ventricular hypertrophy in ESRD patients is multifactorial and includes hypertension, activation of the renin-angiotensin system, increased sympathetic activity, chronic volume overload, chronic anaemia and hyperparathyroidism. In this paper, we review the available experimental and clinical evidence showing the important contribution of the renin-angiotensin system as well as its interaction with the sympathetic nervous system in the pathogenesis of left ventricular hypertrophy in ESRD patients. Furthermore, we summarize the results of currently available clinical studies that examined the effects of angiotensin-converting enzyme inhibition or angiotensin receptor antagonism on left ventricular hypertrophy in ESRD patients, and review evidences that support the use of angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists in the ESRD population.Link_to_subscribed_fulltexKeywords
This publication has 81 references indexed in Scilit:
- Cardiomyocyte loss in experimental renal failure: Prevention by ramiprilKidney International, 2003
- Higher levels of antioxidant defenses in enalapril-treated versus non–enalapril-treated hemodialysis patientsAmerican Journal of Kidney Diseases, 1999
- Advantages of Ang II receptor blockade over ACE inhibition with respect to suppression of sympathetic activity: heartening news for the kidney?Nephrology Dialysis Transplantation, 1999
- Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism and Left Ventricular Hypertrophy in Hemodialysis Patients.Japanese Heart Journal, 1997
- Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertensionThe American Journal of Cardiology, 1996
- Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factorsKidney International, 1995
- An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.JCI Insight, 1990
- Impact of left ventricular hypertrophy on survival in end-stage renal diseaseKidney International, 1989
- Participation of endogenous catecholamines in the regulation of left ventricular mass in progeny of hypertensive parents.Circulation, 1985
- Asymmetric septal hypertrophy and sympathetic overactivity in normotensive hemodialyzed patientsAmerican Heart Journal, 1985